Clinical Trials · NCT02904759

Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Male Subjects

CompletedPhase 3Desmopressin (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Ferring Pharmaceuticals
Enrollment
342
Start date
Sep 2016
Locations
1 site, Japan
Primary endpoint
Change from baseline in mean number of nocturnal voids during 12 weeks of treatment
View Desmopressin compound reference